Skip to main content
. 2022 Mar 29;9:588–596. doi: 10.1016/j.toxrep.2022.03.031

Table 2.

Frequency (%) of erythrocytic nuclear abnormalities (ENAs) of Oreochromis niloticus exposed to fluoxetine for 96 h.

Frequency (%) of ENAs Treatment groups
NC SC 10 µg/L 100 µg/L 1000 µg/L PC
MN 0.04 ± 0.04 0.06 ± 0.03 0.07 ± 0.04 0.24 ± 0.11* 0.26 ± 0.11* 0.56 ± 0.32*
LN 0.05 ± 0.04 0.05 ± 0.04 0.06 ± 0.05 0.07 ± 0.04 0.14 ± 0.08* 0.17 ± 0.08*
BN 0.15 ± 0.06 0.15 ± 0.06 0.16 ± 0.06 0.20 ± 0.07 0.25 ± 0.14 0.72 ± 0.29*
NN 0.20 ± 0.07 0.20 ± 0.06 0.21 ± 0.07 0.26 ± 0.07 0.37 ± 0.14* 0.84 ± 0.35*
KN 0.33 ± 0.15 0.34 ± 0.14 0.36 ± 0.16 0.41 ± 0.15 0.60 ± 0.16* 0.95 ± 0.24*
BC 0.01 ± 0.02 0.01 ± 0.02 0.01 ± 0.02 0.01 ± 0.02 0.01 ± 0.02 0.03 ± 0.05
Total ENAs 0.76 ± 0.20 0.79 ± 0.23 0.86 ± 0.27 1.18 ± 0.20* 1.62 ± 0.48* 3.26 ± 0.64*

The results expressed as mean ± standard deviation. * Statistically significant differences to the negative control group (p < 0.05). NC: negative control group; SC: solvent control group; PC: positive control group; 10, 100, 1000: treatment groups exposed to 10 µg/L, 100 µg/L and 1000 µg/L of FLX, respectively; MN: micronucleus; LN: lobed nucleus; BN: blebbed nucleus; NN: notched nucleus; BC: binucleated cell; KN: kidney-shaped nucleus.